A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs BGB 3111 (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- Sponsors BeiGene
- 10 May 2017 According to a BeiGene media release, the follow-up of enrolled patients is ongoing.
- 22 Mar 2017 According to a BeiGene media release, updated data will be presented in 2017.
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.